首页 > 市场调查报告书 > 製药

精神疾病

市场调查报告书

商品编码

1675282

2025 年至 2033 年忧郁症药物市场报告（依药物类别、疾病类型、药物类型、配销通路和地区划分）

Depression Drugs Market Report by Drug Class, Disorder Type, Drug Type, Distribution Channel, and Region 2025-2033

出版日期: 2025年03月01日 | 出版商:

IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

2024IMARC Group全球抗忧郁药物市场规模达到 192 亿美元。由于久坐的生活方式和压力导致大众抑郁症病例不断增加，药物配方和给药技术的不断进步，以及对行动应用程式和线上治疗平台等数位疗法的偏好日益增加，这些都是推动市场成长的一些因素。

忧郁症是一种精神障碍，其特征是缺乏正面情绪，情绪持续低落，并出现许多认知、身体、行为和情绪症状。诊断是透过识别症状和检查患者的病史来实现的。然后使用忧郁药物进行治疗，该药物可以平衡大脑中神经传导物质（如血清素）的功能并控制患者的情绪和情绪。这些药物可以帮助缓解焦虑、季节性情感障碍和心境恶劣障碍的症状。

根据世界卫生组织 (WHO) 的数据，忧郁症是导致残疾的主要原因之一，影响了全球超过 2.64 亿人。社交焦虑和忧郁等精神障碍的盛行率不断上升，这是推动忧郁药物市场成长的关键因素之一。此外，由于各国政府实施全面封锁并推动社交疏离措施，相当一部分人口的日常生活发生了改变，进而对个人的心理健康产生了负面影响。这一趋势已成为推动抗忧郁药物销售的另一个重要成长因素。此外，随着开发副作用小、效果持久的抗忧郁药物的新技术的出现，以及新药的接受度不断提高，预计将在未来几年推动市场成长。

IMARC 集团的最新报告对全球抗忧郁药物市场进行了深入分析，涵盖了其所有重要方面。内容涵盖从市场的宏观概况到行业表现的微观细节、最新趋势、关键市场驱动因素和挑战、 SWOT 分析、波特五力分析、价值链分析等。

本报告解答的关键问题

全球抗忧郁药物市场规模有多大？ COVID-19 对全球抗忧郁药物市场有何影响？
全球抗忧郁药物市场的预期成长率是多少？
推动全球抗忧郁药物市场发展的关键因素有哪些？
根据疾病类型，全球抗忧郁药物市场如何分布？
根据配销通路，全球抗忧郁药物市场的分布是如何的？
全球抗忧郁药物市场的主要区域有哪些？
全球抗忧郁药物市场的关键公司/参与者有哪些？

The global depression drugs market size reached USD 19.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.1 Billion by 2033, exhibiting a growth rate (CAGR) of 2.9% during 2025-2033. The growing cases of depression among the masses due to sedentary lifestyle and stress, increasing advancements in drug formulation and delivery techniques, and rising preferences for digital therapeutics, such as mobile apps and online therapy platforms, are some of the factors impelling the market growth.

Depression is a mental disorder characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. It is diagnosed by identifying the symptoms and checking the medical history of the patient. It is then treated using depression drugs, which balance the functioning of neurotransmitters, such as serotonin, in the brain and controlling the mood and emotions of the patient. These drugs can assist in relieving the signs of anxiety, seasonal affective disorder and dysthymia.

According to the World Health Organization (WHO), depression is one of the leading causes of disability and has impacted more than 264 million people across the globe. The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth. Moreover, as governments of various countries have imposed complete lockdown and are promoting the adoption of social distancing measures, the everyday routine of a significant portion of the population has been altered, which, in turn, has negatively impacted the mental health of individuals. This trend has emerged as another major growth-inducing factor boosting the sales of depression drugs. Furthermore, the emergence of novel techniques for the development of antidepressants with minimal side-effects and long-term results, in confluence with the increasing acceptance of new medications, is anticipated to impel the market growth in the upcoming years.

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Key Market Segmentation:

Breakup by Drug Class:

Atypical Antipsychotics
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
Selective Serotonin Reuptake Inhibitors (SSRIs)
Central Nervous System (CNS) Stimulants
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Others

Breakup by Disorder Type:

Major Depressive Disorder
Obsessive-Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others

Breakup by Drug Type:

Generic Drugs
Branded Drugs

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Breakup by Region:

North America
Europe
Asia Pacific
Middle East and Africa
Latin America

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report

1.What is the size of the global depression drugs market?
2.What has been the impact of COVID-19 on the global depression drugs market?
3.What is the expected growth rate of the global depression drugs market?
4.What are the key factors driving the global depression drugs market?
5.What is the breakup of the global depression drugs market based on the disorder type?
6.What is the breakup of the global depression drugs market based on the distribution channel?
7.What are the key regions in the global depression drugs market?
8.Who are the key companies/players in the global depression drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Depression Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Drug Class
5.5 Market Breakup by Disorder Type
5.6 Market Breakup by Drug Type
5.7 Market Breakup by Distribution Channel
5.8 Market Breakup by Region
5.9 Market Forecast

6 Market Breakup by Drug Class

6.1 Atypical Antipsychotics
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Selective Serotonin Reuptake Inhibitors (SSRIs)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Central Nervous System (CNS) Stimulants
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Tricyclic Antidepressants
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Monoamine Oxidase Inhibitors
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
6.7 Others
- 6.7.1 Market Trends
- 6.7.2 Market Forecast

7 Market Breakup by Disorder Type

7.1 Major Depressive Disorder
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Obsessive-Compulsive Disorder
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Generalized Anxiety Disorder
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Panic Disorder
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Drug Type

8.1 Generic Drugs
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Branded Drugs
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Europe
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Asia Pacific
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
10.4 Middle East and Africa
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
10.5 Latin America
- 10.5.1 Market Trends
- 10.5.2 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Otsuka Pharmaceutical
- 15.3.2 Pfizer
- 15.3.3 Eli Lilly and Company
- 15.3.4 AstraZeneca
- 15.3.5 Novartis
- 15.3.6 Bristol-Myers Squibb
- 15.3.7 GlaxoSmithKline
- 15.3.8 Takeda Pharmaceutical Company
- 15.3.9 Allergan
- 15.3.10 Johnson & Johnson
- 15.3.11 Zhejiang NHU Company Ltd
- 15.3.12 Sebela Pharmaceuticals

简介目录图表

List of Figures

Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
Figure 2: Global: Depression Drugs Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2024
Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2024
Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2024
Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2024
Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2024
Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 9: Global: Depression Drugs Industry: SWOT Analysis
Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulants) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Depression Drugs (Monoamine Oxidase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million USD), 2019 & 2024
Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2025-2033
Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million USD), 2019 & 2024
Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million USD), 2025-2033
Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million USD), 2019 & 2024
Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million USD), 2025-2033
Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million USD), 2019 & 2024
Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million USD), 2025-2033
Figure 48: North America: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Europe: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million USD), 2025-2033
Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Depression Drugs Market Structure
Table 8: Global: Depression Drugs Market: Key Players

02-2729-4219

+886-2-2729-4219